| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Test panel guides diagnosis of early onset IBD
Answers from the Lab
The incidence of inflammatory bowel disease, or IBD, has rapidly increased — especially among children. In this test-specific episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' gene sequencing panel (Test ID: EOIBD) comprehensively evaluates patients with suspected monogenic early onset IBD.
"The results can be game changers for these patients," Dr. Moyer says. "Testing can not only help establish the diagnosis but also guide therapy."
Monogenic IBD is caused by variance in a single gene. Mayo Clinic Laboratories' test panel covers 107 genes. It's designed to provide greater accuracy than alternative options, such as functional testing, or exome or genome sequencing.
"Our specialized team includes laboratory technologists, genetic counselors, and laboratory directors, who work together to interpret the results for each patient tested," Dr. Moyer says.
Listen to learn more about Mayo Clinic Laboratories' EOIBD test panel.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
